155 related articles for article (PubMed ID: 27144829)
1. Cancer Stem Cells and Chemoresistance in Glioblastoma Multiform: A Review Article.
Safari M; Khoshnevisan A
J Stem Cells; 2015; 10(4):271-85. PubMed ID: 27144829
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma.
Pistollato F; Abbadi S; Rampazzo E; Persano L; Della Puppa A; Frasson C; Sarto E; Scienza R; D'avella D; Basso G
Stem Cells; 2010 May; 28(5):851-62. PubMed ID: 20309962
[TBL] [Abstract][Full Text] [Related]
3. JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.
Okada M; Sato A; Shibuya K; Watanabe E; Seino S; Suzuki S; Seino M; Narita Y; Shibui S; Kayama T; Kitanaka C
Int J Oncol; 2014 Feb; 44(2):591-9. PubMed ID: 24316756
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme.
Johannessen TC; Bjerkvig R
Expert Rev Anticancer Ther; 2012 May; 12(5):635-42. PubMed ID: 22594898
[TBL] [Abstract][Full Text] [Related]
5. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
6. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M
J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186
[TBL] [Abstract][Full Text] [Related]
7. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN
Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979
[TBL] [Abstract][Full Text] [Related]
8. Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents.
Szeliga M; Zgrzywa A; Obara-Michlewska M; Albrecht J
J Neurochem; 2012 Nov; 123(3):428-36. PubMed ID: 22888977
[TBL] [Abstract][Full Text] [Related]
9. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
[TBL] [Abstract][Full Text] [Related]
10. Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma.
Gil Del Alcazar CR; Todorova PK; Habib AA; Mukherjee B; Burma S
Mol Cancer Res; 2016 Oct; 14(10):928-940. PubMed ID: 27358111
[TBL] [Abstract][Full Text] [Related]
11. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
Sato A; Sunayama J; Matsuda K; Seino S; Suzuki K; Watanabe E; Tachibana K; Tomiyama A; Kayama T; Kitanaka C
Stem Cells; 2011 Dec; 29(12):1942-51. PubMed ID: 21957016
[TBL] [Abstract][Full Text] [Related]
12. Chemoresistance and chemotherapy targeting stem-like cells in malignant glioma.
Sørensen MD; Fosmark S; Hellwege S; Beier D; Kristensen BW; Beier CP
Adv Exp Med Biol; 2015; 853():111-38. PubMed ID: 25895710
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.
William D; Walther M; Schneider B; Linnebacher M; Classen CF
PLoS One; 2018; 13(1):e0191511. PubMed ID: 29352318
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
Huang H; Lin H; Zhang X; Li J
Oncol Rep; 2012 Jun; 27(6):2050-6. PubMed ID: 22426504
[TBL] [Abstract][Full Text] [Related]
16. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
Nguyen SA; Stechishin OD; Luchman HA; Lun XQ; Senger DL; Robbins SM; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Sep; 20(18):4894-903. PubMed ID: 25078279
[TBL] [Abstract][Full Text] [Related]
17. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.
Patyka M; Sharifi Z; Petrecca K; Mansure J; Jean-Claude B; Sabri S
Oncotarget; 2016 Sep; 7(37):60245-60269. PubMed ID: 27533246
[TBL] [Abstract][Full Text] [Related]
19. MGMT methylation in glioblastoma: tale of the tail.
Shah N; Schroeder B; Cobbs C
Neuro Oncol; 2015 Jan; 17(1):167-8. PubMed ID: 25395464
[No Abstract] [Full Text] [Related]
20. Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?
Weller M; Wick W; Hegi ME; Stupp R; Tabatabai G
Future Oncol; 2010 Sep; 6(9):1407-14. PubMed ID: 20919826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]